Multiple sclerosis

EQS-News: Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Retrieved on: 
Wednesday, April 10, 2024
Research, Conference, Biotechnology, M.B.A, Nikko Hotels, Multiple sclerosis, PST, RSVP

NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:

Key Points: 
  • NEW YORK, April 4, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following investor conferences in April:
    April 9: Immunic’s MS R&D Day.
  • The MS R&D Day will take place on Tuesday, April 9, 2024, from 10:30 am to 12:30 pm PST in-person at the Hotel Nikko in San Francisco.
  • Dr. Vitt will participate in a fireside chat and one-on-one investor meetings at this virtual conference.
  • A webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

EQS-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Retrieved on: 
Wednesday, April 10, 2024
Biotechnology, Patent, Multiple sclerosis, Calcium, Into, Sclerosis, Pharmaceutical industry

The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.

Key Points: 
  • The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.
  • “Allowance of this key composition-of-matter patent, covering the specific polymorph of vidofludimus calcium, provides another important layer of proprietary intellectual property protection around our lead, late-stage asset,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • “A significant part of this patent will also cover the related method of producing material of vidofludimus calcium used in our studies.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

Retrieved on: 
Thursday, April 4, 2024
Rituximab, Multiple sclerosis, ALS, Insulin, Patient, Warsaw Stock Exchange, GMP, PTG, Therapy, Marketing, Autoimmune disease, PD-1, Pharmaceutical industry

This three-arm trial had earlier shown that 50% of PTG-007-treated patients in combination with rituximab were still in remission after 24 months.

Key Points: 
  • This three-arm trial had earlier shown that 50% of PTG-007-treated patients in combination with rituximab were still in remission after 24 months.
  • PolTREG CEO Piotr Trzonkowski, who co-authored the peer-reviewed study, said: “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies.
  • We have treated over 100 patients with our cell therapy at our facility over the last 17 years.
  • Having a biomarker of efficacy, like PD-1+ T-cells, could facilitate doctors’ ability to monitor their patients’ responses to therapy.

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Retrieved on: 
Tuesday, March 26, 2024
OCT, Optical coherence tomography, Patent, Multiple sclerosis, Capsule, Tablet, Code, MD, SPRINT, MPH, Tokyo Stock Exchange, Pharmaceutical industry

Once issued, this patent is expected to expire no earlier than October 2039.

Key Points: 
  • Once issued, this patent is expected to expire no earlier than October 2039.
  • The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
  • The allowed claims specifically cover both primary progressive multiple sclerosis and secondary progressive multiple sclerosis.
  • Previously, we reported positive Optical Coherence Tomography (OCT) results from the SPRINT-MS Phase 2b trial of MN-166 in progressive multiple sclerosis.

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Monday, April 8, 2024
Digital health, Disease, Caregiver, Partnership, Novartis, PNH, Patient, Conditional sentence, Multiple sclerosis, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.

Key Points: 
  • This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.
  • Ekiva PNH is tailored to the specific needs of the PNH patient population, offering enhanced functionalities for supporting bespoke care and setting a new standard in patient personalization.
  • Ekiva addresses these challenges by providing a comprehensive digital platform that empowers a patient reducing the uncertainties associated with disease management.
  • With the launch of Ekiva PNH, Dawn Health and Novartis reaffirm their position at the forefront of digital innovation in healthcare, setting a new standard in the management of rare chronic diseases.

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Monday, April 8, 2024
Digital health, Disease, Caregiver, Partnership, Novartis, PNH, Patient, Conditional sentence, Multiple sclerosis, Paroxysmal nocturnal hemoglobinuria, Pharmaceutical industry

This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.

Key Points: 
  • This latest Ekiva product launch signifies not only a continuation of the innovative and collaborative efforts between Dawn Health and Novartis, but also illustrates the customizability and efficiency of the modular Dawn platform.
  • Ekiva PNH is tailored to the specific needs of the PNH patient population, offering enhanced functionalities for supporting bespoke care and setting a new standard in patient personalization.
  • Ekiva addresses these challenges by providing a comprehensive digital platform that empowers a patient reducing the uncertainties associated with disease management.
  • With the launch of Ekiva PNH, Dawn Health and Novartis reaffirm their position at the forefront of digital innovation in healthcare, setting a new standard in the management of rare chronic diseases.

Illinois Lottery Reports Half-Year Results

Retrieved on: 
Tuesday, March 19, 2024
DREAM, Homelessness, HIV/AIDS, BP, General counsel, Education, Lotto, Multiple sclerosis, Special Olympics, Olympic Games, Illinois State Lottery, Breast cancer, UNCF, Fiscal year

CHICAGO, March 19, 2024 (GLOBE NEWSWIRE) -- The Illinois Lottery today announced its results for the first six months of the 2024 fiscal year, in which the Lottery has generated $1.9 billion in sales leading to estimated returns to the State of Illinois of $456 million so far.

Key Points: 
  • CHICAGO, March 19, 2024 (GLOBE NEWSWIRE) -- The Illinois Lottery today announced its results for the first six months of the 2024 fiscal year, in which the Lottery has generated $1.9 billion in sales leading to estimated returns to the State of Illinois of $456 million so far.
  • Additionally, the Illinois Lottery raised over $4.1 million in the first half of the 2024 fiscal year for good causes in Illinois.
  • The Lottery has contributed more than $24 billion in revenue to educational funding in Illinois,” said Harold Mays, Illinois Lottery Director.
  • During the fiscal period, the Illinois Lottery launched its first-ever $50 Instant Ticket.

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

Retrieved on: 
Tuesday, March 19, 2024
Motivation, Mouse, Multiple sclerosis, Capital market, ASA, Immune system, Summit, Poster, Drug development, Vaccine

Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases.

Key Points: 
  • Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to develop high-precision treatments for autoimmune diseases.
  • At the conference, Nykode demonstrated for the first time a significant effect in a therapeutic setting in a preclinical model for Multiple Sclerosis (MS) with its inverse vaccine platform.
  • The data also illustrate the strong contribution of the specific targeting unit and confirm that the disease protection is antigen-specific, underscoring the potential of Nykode’s technology in the field of autoimmune diseases.
  • In addition to an oral presentation, Nykode presented a poster at the Summit to elaborate on these findings.

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Retrieved on: 
Friday, March 15, 2024
Pharmacology, Toxicity, Protein corona, Brain, Plasma, Longevity, Multiple sclerosis, BBB, ALS, CNM, University college, Medicine, Gastrointestinal tract, Research, Gold, Blood, Traffic barrier, Radiology, Protein, Clinical trial, CSO, Neurodegenerative disease, Apolipoprotein, Research fellow, Copper

Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically.

Key Points: 
  • Simultaneously, the depletion of opsonin-based proteins in the corona extends their circulation time in the blood, as observed clinically.
  • “When we invented the electro-crystal-chemical method to grow clean-surfaced, highly faceted gold nanocrystals, we certainly had catalytic optimization in mind.
  • However, we also understood that the protein corona can control the location of our nanocrystals in vivo.
  • A Phase 3 registrational clinical trial of CNM-Au8 for the treatment of the progressive neurodegenerative disease, amyotrophic lateral sclerosis, is presently planned to launch in 2024.